Core Viewpoint - Cannabis stocks experienced a significant surge, with Tilray Brands rising over 32%, Canopy Growth increasing over 23%, SNDL up over 19%, Aurora Cannabis rising over 11%, and Cronos Group gaining over 5% due to reports that President Donald Trump is considering reclassifying cannabis to a lower risk category [1] Group 1 - Tilray Brands (TLRY.US) saw an increase of over 32% [1] - Canopy Growth (CGC.US) rose by more than 23% [1] - SNDL (SNDL.US) increased by over 19% [1] - Aurora Cannabis (ACB.US) experienced a rise of over 11% [1] - Cronos Group (CRON.US) gained over 5% [1] Group 2 - Reports indicate that President Trump is expected to push for the reclassification of cannabis as a "lower risk drug" [1] - Trump is considering moving cannabis from Schedule I, which indicates no medical use and high abuse potential, to Schedule III, which includes substances with lower dependency and addiction potential [1]

Core Viewpoint - Cannabis stocks experienced a significant surge, with Tilray Brands (TLRY.US) rising over 32%, Canopy Growth (CGC.US) increasing over 23%, SNDL (SNDL.US) up over 19%, Aurora Cannabis (ACB.US) gaining over 11%, and Cronos Group (CRON.US) climbing over 5% due to reports that President Donald Trump is considering reclassifying cannabis to a lower harm category [1] Group 1 - Tilray Brands (TLRY.US) saw an increase of over 32% [1] - Canopy Growth (CGC.US) rose by more than 23% [1] - SNDL (SNDL.US) experienced a gain of over 19% [1] Group 2 - Aurora Cannabis (ACB.US) increased by more than 11% [1] - Cronos Group (CRON.US) rose by over 5% [1] - Reports indicate that Trump is considering moving cannabis from Schedule I to Schedule III, indicating a potential shift in regulatory stance [1]

Core Insights - The reclassification of the drug is expected to alleviate tax burdens on cannabis companies [1] Industry Impact - Cannabis companies will benefit from reduced tax liabilities due to the reclassification of the drug [1]

Core Viewpoint - The stock prices of major cannabis companies surged significantly following reports of President Trump's plans to relax federal regulations on marijuana, with notable increases in premarket trading [1][2]. Group 1: Stock Price Movements - Tilray Brands (NASDAQ:TLRY) saw a price increase of 34.88%, while Canopy Growth (NASDAQ:CGC) rose by 27.46% in premarket trading [1]. - Other companies also experienced substantial gains: Aurora Cannabis Inc. (NASDAQ:ACB) surged 20%, Cronos Group Inc. (NASDAQ:CRON) gained 19%, Organigram Global Inc. (NASDAQ:OGI) rose 12%, and SNDL Inc. (NASDAQ:SNDL) increased by 34.7% [1]. Group 2: Regulatory Changes - The surge in stock prices was attributed to news that Trump plans to instruct federal agencies to reclassify marijuana as a Schedule III drug, which would change its regulatory status [2][3]. - This reclassification would subject cannabis companies to different tax regulations, potentially attracting more investments and placing marijuana in the same category as substances like steroids and Tylenol with codeine [3]. Group 3: Historical Context - Trump had previously hinted at this reclassification in August, indicating a consistent approach towards cannabis regulation [3]. - The anticipated change is expected to occur early next year, moving marijuana from a category that includes heroin to a lower tier for less dangerous substances [4].

Group 1 - The article provides a market analysis of Tilray Inc., focusing on its performance and potential investment opportunities in the cannabis industry [1] - Tilray Inc. has shown significant growth in revenue, with a reported increase of 20% year-over-year, reaching $250 million in the last fiscal year [1] - The company is expanding its product offerings and market reach, particularly in the European market, which is expected to drive future growth [1] Group 2 - The cannabis industry is experiencing increased demand, with projections indicating a market size of $50 billion by 2025, driven by legalization and consumer acceptance [1] - Regulatory changes in various regions are creating new opportunities for companies like Tilray, enhancing their competitive positioning [1] - The article highlights the importance of strategic partnerships and acquisitions in strengthening Tilray's market presence and operational capabilities [1]

Core Viewpoint - The potential reclassification of cannabis by President Trump from Schedule I to Schedule III is expected to significantly benefit the cannabis industry, leading to a surge in stock prices for major cannabis producers in the U.S. [1][2] Group 1: Market Reaction - Major cannabis producers saw substantial stock price increases in pre-market trading, with Tilray Brands (TLRY.US) rising over 30%, Canopy Growth (CGC.US) up 23%, Aurora Cannabis (ACB.US) increasing by 20%, SNDL (SNDL.US) gaining 14%, and Cronos Group (CRON.US) up 12% [1] - The market response indicates strong investor optimism regarding the potential regulatory changes surrounding cannabis [1] Group 2: Regulatory Context - President Trump is considering moving cannabis from Schedule I, which indicates no medical use and high abuse potential, to Schedule III, which includes substances with accepted medical uses but some potential for abuse [1][2] - Schedule III drugs include substances like ketamine and anabolic steroids, while Schedule I includes LSD and heroin [2] - The Biden administration previously proposed a similar reclassification in March 2024, but the DEA canceled related hearings [2] Group 3: Political and Industry Implications - Trump's discussions with key officials and cannabis industry executives suggest a serious consideration of the reclassification, which could alleviate criminal penalties for personal use and remove certain federal tax and business barriers [2] - The reclassification could improve the operating environment for legal cannabis businesses and their employees [2] - Robert F. Kennedy Jr., nominated by Trump for the Department of Health and Human Services, has advocated for ending cannabis criminalization and implementing a regulated sales system [3]

Core Insights - Tilray Brands stock price has rebounded significantly, rising to $8.43 after a recent surge, indicating positive market sentiment and potential for further acceleration as new catalysts emerge [1] Company Summary - The stock price increase occurred shortly after the company completed a significant milestone, suggesting that recent developments may be influencing investor confidence and market performance [1]

Group 1 - Cannabis stocks experienced significant gains, with Tilray Brands surging over 28% and Canopy Growth jumping 23% in premarket trading [1] - Innovative Industrial Properties, a cannabis facility operator, also saw an increase of more than 6% [1] - The surge in cannabis stocks was attributed to reports of President Donald Trump planning to ease federal restrictions on marijuana [1] Group 2 - Trump is expected to instruct agencies to reclassify marijuana as a Schedule III drug, which would alter tax regulations for cannabis companies and promote investment [2] - The reclassification would move marijuana from a category that includes heroin to a lower tier with less dangerous drugs, such as steroids and Tylenol with codeine, and is anticipated to occur early next year [2] - This change in classification was previously suggested by Trump in August, highlighting ongoing discussions about marijuana's legal status [3] Group 3 - Despite broader acceptance of cannabis, pot stocks have faced challenges since many went public approximately seven years ago, with Tilray shares down 36% prior to the recent surge [3]

Market Overview - U.S. stock futures showed mixed performance following a mixed close on Thursday, with major indices experiencing fluctuations [1] - The Dow Jones increased by over 600 points, indicating a rotation out of expensive tech stocks, while overall risk appetite remained strong after the Federal Reserve's third consecutive interest-rate cut [1] Economic Indicators - The 10-year Treasury bond yielded 4.17%, while the two-year bond was at 3.53%, with a 73.4% likelihood of the Federal Reserve maintaining current interest rates [2] Futures Performance - Dow Jones futures increased by 0.17%, while S&P 500 and Nasdaq 100 futures decreased by 0.19% and 0.54%, respectively [3] Stocks in Focus - Costco Wholesale Corp. reported better-than-expected financial results for Q1 of fiscal 2026 but saw a premarket decline of 0.52% [7] - Broadcom Inc. dropped 5.18% due to disappointing guidance regarding gross margins and a higher tax rate for fiscal 2026 [7] - Lululemon Athletica Inc. surged 9.49% after exceeding Q3 expectations and raising full-year guidance [16] - RH experienced a 4.26% increase despite mixed Q3 results, reporting earnings of $1.71 per share, missing estimates [16] - Tilray Brands Inc. rose 28.11% following the announcement of its new product line [16] Analyst Insights - Scott Wren from Wells Fargo anticipates moderate growth and easing price pressures in the U.S. economy, projecting S&P 500 earnings growth of slightly over 11% [12] - Wren recommends active management and suggests reallocating funds from Communication Services and Information Technology to sectors like Financials, Industrials, and Utilities, which are expected to benefit from AI capital expenditures [13][14]

Core Viewpoint - cbdMD Inc. has regained full compliance with NYSE American listing standards, resulting in a significant increase in its stock price by 54.64% in after-hours trading, reaching $0.98 from a previous close of $0.63 [1][2]. Group 1: Compliance and Listing Status - The NYSE American removed cbdMD's ".BC" noncompliant issuer label, indicating that deficiencies related to shareholders' equity and net loss requirements have been resolved [2]. - The company remains subject to NYSE American's continued listing monitoring procedures, emphasizing its commitment to strong financial discipline and governance [3]. Group 2: Financial Strategy and Achievements - The CEO of cbdMD highlighted that regaining the NYSE American listing is a critical achievement, reflecting efforts to strengthen the company's balance sheet through actions such as the Series A preferred share conversion in May and a capital raise in September [4]. - The company has a market capitalization of $5.58 million and has experienced an 80.94% decline in stock price year to date, with a 52-week trading range of $0.47 to $6.54 [5]. Group 3: Trading Metrics - The stock is currently experiencing long-term consolidation with medium and short-term upward movement, as indicated by Benzinga's Edge Stock Rankings [5].